editor@hikmahplus.com ISSN: 2XXX-XXXX (Online)
Review Article Research Methods

Protocol for Systematic Review and Meta-Analysis of Pharmacological Interventions in MAFLD: GLP-1 Receptor Agonists as an Exemplar

Authors: Surtika Tamilwanan, Department of Pharmacology, Faculty of Pharmacy & Bio-Medical Sciences, MAHSA University, Selangor 42610, Malaysia Rofaida Alshehade*, Faculty of Pharmacy, Al-Zaytoonah University of Jordan, Amman 11733, Jordan rofaida.alshehade@zuj.edu.jo *Corresponding author
Volume: 1 | Issue: 1 | Pages: 8-18 | Published: Feb 01, 2026
Email
0 0
Article Metrics

Track mentions across social media, news, and blogs.

View details
Quick Access
QR Code

Scan with your phone to read this article on mobile

Abstract

Metabolic-associated fatty liver disease (MAFLD) affects approximately 25% of the global population, yet pharmacological treatment options remain limited despite potentially severe complications. Multiple drug classes are under investigation, necessitating standardized evidence-synthesis methodologies that account for disease heterogeneity. Notably, different experimental models used in preclinical research can yield distinct gene expression profiles affecting lipid metabolism, inflammation, and fibrogenesis pathways, which must be considered when translating findings to clinical applications.

This protocol describes the methodology for conducting a systematic review and meta-analysis evaluating the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in adults with metabolic-associated fatty liver disease (MAFLD). While the protocol focuses specifically on GLP-1 RAs, the rigorous methodological approaches described here—including disease stage stratification, standardized outcome assessment, and comprehensive quality evaluation, may serve as a reference for future systematic reviews of other pharmacological interventions in MAFLD.

The protocol follows PRISMA-P guidelines for literature searching, study selection, data extraction with international unit standardization, quality assessment using the Cochrane Risk of Bias Tool 2 and GRADE approach, and statistical meta-analysis. Specific attention is given to disease severity stratification, intervention characteristics, and patient populations.

This systematic review will provide comprehensive evidence on GLP-1 RA efficacy and safety across the MAFLD spectrum, focusing on stage-specific outcomes. Findings will inform clinical decision-making, identify knowledge gaps, and guide future research.

Keywords:
Metabolic-associated fatty liver disease Systematic review Meta-analysis GLP-1 receptor agonists Pharmacological interventions

Full Article

Click "View PDF" to read the article inline, or download for offline reading.

Article History

Submitted: Dec 15, 2025
Accepted: Jan 10, 2026
Published: Feb 01, 2026

Rights & Permissions

No References Available

References for this article have not been provided.

Author Information

Surtika Tamilwanan

Department of Pharmacology, Faculty of Pharmacy & Bio-Medical Sciences, MAHSA University, Selangor 42610, Malaysia

Rofaida Alshehade Corresponding

Faculty of Pharmacy, Al-Zaytoonah University of Jordan, Amman 11733, Jordan

Cited By

Loading...

Checking CrossRef for citations...

Citation data provided by CrossRef. Search on CrossRef →

Article Versions

Current Version of Record - Published Feb 01, 2026
Last updated: Mar 20, 2026

No corrections or errata have been issued for this article.

How to Cite

Tamilwanan, S., Alshehade, R. (2026). Protocol for Systematic Review and Meta-Analysis of Pharmacological Interventions in MAFLD: GLP-1 Receptor Agonists as an Exemplar. Biomedicasphere, 1(1), 8-18. https://doi.org/10.59324/bmsj.2026.1(1).02